Springer Healthcare | Adis
PharmacoEconomics
Contact information of Springer Healthcare | Adis:
Web page: http://pharmacoeconomics.adisonline.com/
To be notified about new items in this series:
Register for eTOC http://pharmacoeconomics.adisonline.com/pt/re/phe/etocs.htm (see also NEP)
Download restrictions: Pay per view
Editor:
For corrections or technical questions regarding this series, please contact
(Dave Dustin)
Series handle: repec:wkh:phecon
Citations RSS feed: at CitEc
Impact factors:
Simple,
Recursive,
Discounted,
Recursive discounted,
H-Index,
Aggregate
Access and download statistics
Top item: By citations. By downloads (last 12 months).
More pages of listings: 0| 1| 2| 3| 4| 5| 6| 7
2000, Volume 17, Issue 4
- 351-360 Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine
by A. Brett Hauber & Ari Gnanasakthy & Edward H. Snyder & Mohan V. Bala & Anke Richter & Josephine A. Mauskopf - 361-370 Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy: A Comparison of Raltitrexed and Fluorouracil plus Folinic Acid
by Mark Sculpher & Michael K. Palmer & Anne Heyes - 371-382 Initial Treatment Choice in Depression: Impact on Medical Expenditures
by Eric T. Edgell & Timothy R. Hylan & JoLaine R. Draugalis & Stephen Joel Coons - 383-389 Cost Analysis of the Treatment of Schizophrenia in the UK: A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol
by Stephen Almond & Owen O'Donnell - 391-401 Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia
by Amnon Sonnenberg
2000, Volume 17, Issue 3
- 227-236 Bridging Decision Analytic Modelling with a Cross-Sectional Study: Application to Parkinson's Disease
by Mark J.C. Nuijten - 237-243 ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations
by Andrew P. Davie - 245-262 Clinical and Economic Factors Important to Anaesthetic Choice for Day-Case Surgery
by Edmond I. Eger & Paul F. White & Martin S. Bogetz - 263-272 Evaluating the Potential
by Eric L. Eisenstein & Eric D. Peterson & James G. Jollis & Barbara E. Tardiff & Robert M. Califf & J. David Knight & Daniel B. Mark - 273-286 Assessing Health Utilities in Schizophrenia: A Feasibility Study
by Lakshmi N. Voruganti & A. George Awad & L. Kola Oyewumi & Leonardo Cortese & Sandra Zirul & Ravinder Dhawan - 287-293 Economics of the Antithymocyte Globulins Thymoglobulin(R) and Atgam(R) in the Treatment of Acute Renal Transplant Rejection
by Mark A. Schnitzler & Robert S. Woodward & Jeffrey A. Lowell & Leah Amir & Timothy J. Schroeder & Gary G. Singer & Daniel C. Brennan - 295-304 The Cost Effectiveness of Misoprostol Prophylaxis Alongside Long Term Nonsteroidal Anti-Inflammatory Drugs: Implications of the MUCOSA Trial
by Peter J. Davey & Eric Meyer - 304-314 Household Income Losses Associated With Ischaemic Heart Disease For US Employees
by Jeph Herrin & Charles B. Cangialose & Stephen J. Boccuzzi & William S. Weintraub & David J. Ballard
2000, Volume 17, Issue 2
- 115-120 Diagnosis Related Group Costs in a Regulated Environment: A Note About Their Economic Interpretation
by Claude Le Pen & Gilles Berdeaux - 121-132 New Generation Aromatase Inhibitors in Breast Cancer: Weighing Out Potential Costs and Benefits
by Gerald M. Higa - 133-150 Pharmacoeconomic Considerations in Treating Ovarian Cancer
by Diane Bodurka-Bevers & Charlotte C. Sun & David M. Gershenson - 151-165 Valuing Health-Related Quality of Life: A Review of Health State Valuation Techniques
by Colin Green & John Brazier & Mark Deverill - 167-174 The Costs of Pharmacological Treatment for Major Depression: The Italian Prospective Multicentre Observational Incidence-Based Study
by Rosanna Tarricone & Giovanni Fattore & Simone Gerzeli & Giulio Serra & Cristina Taddei & Mauro Percudani - 175-185 Pharmacoeconomics and Clinical Practice Guidelines: A Survey of Attitudes in Swedish Formulary Committees
by Anders Anell & Patrick Svarvar - 187-195 Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza
by Fred Y. Aoki & Douglas M. Fleming & Adrian D. Griffin & Loretto A. Lacey & Sally Edmundson - 197-208 Cost-of-Illness of Epilepsy in Italy: Data from a Multicentre Observational Study (Episcreen)
by P. Berto & P. Tinuper & S. Viaggi - 209-221 Economic Analysis of Long Term Reversible Contraceptives: Focus on Implanon(R)
by Ceri J. Phillips
2000, Volume 17, Issue 1
- 1-12 Formulary Management of Low Molecular Weight Heparins
by William E. Wade & Bradley C. Martin & Jeffrey A. Kotzan & William J. Spruill & Marie A. Chisoholm & Matthew Perri - 13-35 A Comparative Review of Generic Quality-of-Life Instruments
by Stephen Joel Coons & Sumati Rao & Dorothy L. Keininger & Ron D. Hays - 37-52 Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany
by Peter K. Schadlich & Josef G. Brecht - 53-69 Use and Cost of Hospital and Community Service Provision for Children with HIV Infection at an English HIV Referral Centre
by Eduard J. Beck & Sundhiya Mandalia & Rebecca Griffith & Jeni Beecham & M. D. Sam Walters & Mary Boulton & David L. Miller - 71-76 The Cost of Urinary Incontinence in Italian Women: A Cross-Sectional Study
by Fabrizio Tediosi & Fabio Parazzini & Angela Bortolotti & Livio Garattini - 77-107 Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model: For a Hypothetical Managed-Care Plan of 100 000 Members
by Howard L. Tan - 109 Estimating the Long Term Cost Savings from the Treatment of Alzheimer's Disease: A Modelling Approach
by Peter J. Neumann
1999, Volume 16, Issue 6
- 599-603 The Doctor-Patient Relationship and Prescribing Patterns: A View from Primary Care
by Doug T. Steinke & Thomas M. MacDonald & Peter G. Davey - 605-625 Measuring Quality of Life in Paediatric Patients
by Melinda A. Connolly & Jeffrey A. Johnson - 627-647 Diagnosis and Management of Osteomyelitis: Decision Analytic and Pharmacoeconomic Considerations
by Manouche Tavakoli & Peter Davey & Benedict A. Clift & Huw T. O. Davies - 649-660 Managing Pharmaceutical Expenditure while Increasing Access: The Pharmaceutical Management Agency (PHARMAC) Experience
by Richard Braae & Wayne McNee & David Moore - 661-668 The Effect of Generic Competition on Prescription to Over-the-Counter Switching
by Christopher S. Hollenbeak - 669-678 Health Economics in the Canadian Pharmaceutical Industry
by Lila Assiff & Michael R. Pollock & Patricia Manzi & Ben Faienza & Devidas Menon - 679-697 Economic Evaluation of Long Term Management Strategies for Erosive Oesophagitis
by Ron Goeree & Bernie O'Brien & Richard Hunt & Gordon Blackhouse & Andrew Willan & Jan Watson - 699-709 Annual Cost of Erectile Dysfunction to UK Society
by Jonathan M. Plumb & Julian F. Guest - 711-741 Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation
by Christopher J. Dunn & Rachel H. Foster - 743-755 Acamprosate: Pharmacoeconomic Implications of Therapy
by Rachel H. Foster & Karen J. McClellan
1999, Volume 16, Issue 5
- 425-432 Pharmacoeconomics and Health Policy: Current Applications and Prospects for the Future
by Paul E. Greenberg & Almudena Arcelus & Howard G. Birnbaum & Pierre-Yves Cremieux & Jacques LeLorier & Pierre Ouellette & Mitchell B. Slavin - 433-448 Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis: A Review
by Michael B. Nichol & Ann S. M. Harada - 449-458 Real World Designs in Economic Evaluation: Bridging the Gap Between Clinical Research and Policy-Making
by Rob Baltussen & Reiner Leidl & Andre Ament - 459-472 Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia
by Pierre-Yves Cremieux & Stan N. Finkelstein & Ernst R. Berndt & Jeffrey Crawford & Mitchell B. Slavin - 473-482 Linking Health-Related Quality-of-Life Indicators to Large National Data Sets
by John A. Rizzo & Jody L. Sindelar - 483-497 Cost Effectiveness of Omeprazole and Ranitidine in Intermittent Treatment of Symptomatic Gastro-Oesophageal Reflux Disease
by Nils-Olov Stalhammar & Jonas Carlsson & Robert Peacock & Stefan Mullerlissner & Marcandre Bigard & Gabriele B. Porro & Julio Ponce & James Hosie & Mairi Scott & Donald G. Weir & Claire Fulton & Keith Gillon & Karna D. Bardhan - 499-520 Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year
by George Torrance & Valery Walker & Ronald Grossman & Jayanti Mukherjee & David Vaughan & Jacques La Forge & Noel Lampron - 525-531 Cost Effectiveness of Fluticasone Propionate and Flunisolide in the Treatment of Corticosteroid-Naive Patients with Moderate Asthma
by Timm Volmer & Adrian Kielhorn & Hans H. Weber & Karl J. Wiessmann - 533-542 Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes: A Canadian Hospital Perspective
by Robert M. Balen & Carlo A. Marra & Peter J. Zed & Marc Cohen & Luciana Frighetto - 543-550 Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B Monotherapy: Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients in the UK
by Terry N. Flynn & Stephen M. Kelsey & Dena L. Hazel & Julian F. Guest - 551-561 Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
by Daniel J. Walters & Joseph S. Solomkin & Joseph A. Paladino - 563-576 Economic Impact of Providing Workplace Influenza Vaccination: A Model and Case Study Application at a Brazilian Pharma-Chemical Company
by Emmanuel Burckel & Talat Ashraf & Jose P. Galvao de Sousa Filho & Eduardo Forleo Neto & Hubert Guarino & Caio Yauti & Fernando de Barros Barreto & Louis Champion - 577-593 Cost-Effectiveness Analysis of Antiplatelet Therapy in the Prevention of Recurrent Stroke in the UK: Aspirin, Dipyridamole and Aspirin-Dipyridamole
by Mike Chambers & John Hutton & John Gladman
1999, Volume 16, Issue 4
- 321-328 Herbal Remedies: Issues in Licensing and Economic Evaluation
by Darren M. Ashcroft & Alain Li Wan Po - 329-341 Therapeutic Options in the Treatment of Multiple Myeloma: Pharmacoeconomic and Quality-of-Life Considerations
by Finn Wisloff & Nina Gulbrandsen & Erik Nord - 343-353 Clinical and Economic Considerations of Empirical Antibacterial Therapy of Febrile Neutropenia in Cancer
by George Dranitsaris - 355-365 Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy: A Randomised Controlled Trial in Patients with Continuing Pain After Duodenal Ulcer
by Manouche Tavakoli & Andrzej T. Prach & Mo Malek & David Hopwood & Bernard W. Senior & Frank E. Murray - 367-377 Economic Evaluation of the Treatment of Chronic Wounds: Hydroactive Wound Dressings in Combination with Enzymatic Ointment Versus Gauze Dressings in Patients with Pressure Ulcer and Venous Leg Ulcer in Germany
by Rito Bergemann & Karl W. Lauterbach & Wolfgang Vanscheidt & Klaus-Dieter Neander & Reinhard Engst - 379-397 Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
by Mark Nuijten & Liebeth Meester & Franz Waibel & Suzanne Wait - 399-407 Costs Associated with Symptomatic Systolic Heart Failure
by Peter G. Davey & Peter B. Clarkson & Alex McMahon & Thomas M. MacDonald - 409-416 Costs of Mini Mental State Examination-Related Cognitive Impairment
by Linus Jonsson & Peter Lindgren & Anders Wimo & Bengt Jonsson & Bengt Winblad - 417-419 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects. The Authors Reply
by Sam S. Salek & Melvyn D. Walker & Anthony J. Bayer - 417-419 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
by Stephen P. McKenna & Lynda C. Doward
1999, Volume 16, Issue 3
- 211-224 Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada: Structure, Application and Manufacturer Responsibilities
by Paul C. Langley - 225-246 Formulary Management of Proton Pump Inhibitors
by Michael F. Byrne & Frank E. Murray - 247-271 A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure
by Colin Berry & John McMurray - 273-283 Pharmacotherapeutic Circles: Results of an 18-Month Peer-Review Prescribing-Improvement Programme for General Practitioners
by Liselotte von Ferber & Jurgen Bausch & Ingrid Koster & Ingrid Schubert & Peter Ihle - 285-295 Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed-Care Population
by Scott D. Ramsey & Katherine Newton & David Blough & David K. McCulloch & Nirmala Sandhu & Edward H. Wagner - 297-306 Cost Effectiveness of Helicobacter pylori Eradication Therapies in Patients with Duodenal Ulcer: An Analysis of Triple Therapy Versus Two Dual Therapy Alternatives
by Gunnel R. Tennvall & Anna Norinder & Bo Ohlin - 307-315 Decreased Medical Expenditures for Care of HIV-Seropositive Patients: The Impact of Highly Active Antiretroviral Therapy at a US Veterans Affairs Medical Center
by Larry Mole & Kimberly Ockrim & Mark Holodniy
1999, Volume 16, Issue 2
- 119-125 Challenges to the Economic Evaluation of New Biotechnological Interventions in Healthcare
by James Mason - 127-140 A Review of Quality-of-Life Evaluations in Prostate Cancer
by Sunshine D. Sommers & Scott D. Ramsey - 141-152 Review of Quality-of-Life Evaluations in Patients with Angina Pectoris
by Afschin Gandjour & Karl W. Lauterbach - 153-163 Cost Effectiveness of Riluzole in Amyotrophic Lateral Sclerosis
by Andrea Messori & Sabrina Trippoli & Paola Becagli & Gaetano Zaccara - 165-174 Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach
by Paul Fenn & Alastair Gray - 175-181 The Influence of Hospital-Based Prescribers on Prescribing in General Practice
by John Feely & Robert Chan & John McManus & Brendan O'Shea - 183-192 Cost Comparison of Antibacterial Therapies for Serious Infections: A New Zealand 3-Hospital Study
by W. Guy Scott & Helen M. Scott & Seton Henderson & Alison Inder & Joanne Sanders & Ruth Spearing & Colin McArthur & James Judson & Bartrum Baker & Peter Hicks & Philippa Cotterell - 193-205 Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada
by Stephen Morris & Ed Godber
1999, Volume 16, Issue 1
- 1-8 Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses
by Howard G. Birnbaum & Pierre Y. Cremieux & Paul E. Greenberg & Jacques LeLorier & JoAnn Ostrander & Laura Venditti - 9-16 The Pharmacoeconomics of Hormone Replacement Therapy
by David J Torgerson & David M Reid - 17-31 Benefit Valuation in Economic Evaluation of Cancer Therapies: A Systematic Review of the Published Literature
by Jackie Brown & Mark Sculpher - 33-41 Measuring Sensitivity in Pharmacoeconomic Studies: Refining Point Sensitivity and Range Sensitivity by Incorporating Probability Distributions
by Mark J.C. Nuijten - 43-57 Economic Analysis of Carboplatin Versus Cisplatin in Lung and Ovarian Cancer
by Zeba M. Khan & Karen L. Rascati & Jim M. Koeller - 59-69 Cost of Illness and Disease Severity in a Cohort of French Patients with Parkinson's Disease
by Claude Le Pen & Suzanne Wait & Frederic Moutard-Martin & Max Dujardin & Marc Ziegler - 71-84 Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients with AIDS
by Anita Rachlis & Fiona Smaill & Valery Walker & Lorraine Hotchkies & Amy Jones - 85-98 Diclofenac/Misoprostol: Pharmacoeconomic Implications of Therapy
by Greg L. Plosker & Harriet M. Lamb - 99-114 Donepezil: Pharmacoeconomic Implications of Therapy
by Rachel H. Foster & Greg L. Plosker
1999, Volume 15, Issue 6
- 519-533 Outstanding Regulatory Aspects in the European Pharmaceutical Market
by Panos Kanavos & Elias Mossialos - 535-550 Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure: The Consequences of Underprescribing
by Fredrik Andersson & Charles Cline & Tina Ryden-Bergsten & Leif Erhardt - 551-560 Standard Cost Lists for Healthcare in Canada: Issues in Validity and Inter-Provincial Consolidation
by Philip Jacobs & Noralou P. Roos - 561-572 Hospital Selection for Unit Cost Estimates in Multicentre Economic Evaluations: Does the Choice of Hospitals Make a Difference?
by Ron Goeree & Amiram Gafni & Mary Hannah & Terri Myhr & Gordon Blackhouse - 573-582 A Model to Compute the Medical Cost of Patients in Intensive Care
by Carine Chaix & Isabelle Durand-Zaleski & Corinne Alberti & Christian Brun-Buisson - 583-595 Costs of Diabetes: A Methodological Analysis of the Literature
by Eva Pagano & Massimo Brunetti & Fabrizio Tediosi & Livio Garattini - 597-610 Cost of Schizophrenia to UK Society: An Incidence-Based Cost-of-Illness Model for the First 5 Years Following Diagnosis
by Julian F. Guest & Ron F. Cookson - 611-640 Olanzapine: A Pharmacoeconomic Review of its Use in Schizophrenia
by Rachel H. Foster & Karen L. Goa - 641-644 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
by Sam S. Salek & Melvyn D. Walker & Anthony J. Bayer - 641-644 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
by Marianne Greer & Helma Monteban
1999, Volume 15, Issue 5
- 423-434 Pharmacoeconomic Evaluation in the Real World: Effectiveness Versus Efficacy Studies
by Dennis A. Revicki & Lori Frank - 435-443 Prescribing at the Interface Between Primary and Secondary Care in the UK: Towards Joint Formularies?
by Martin Duerden & Tom Walley - 445-458 Counting the Costs of Drug-Related Adverse Events
by T. Jeffrey White & Annet Arakelian & Jay P. Rho - 459-468 The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
by Judith L. Glennie & George W. Torrance & Jean Francois Baladi & Catherine Berka & Eleanor Hubbard & Devidas Menon & Nick Otten & Marc Riviere - 469-480 Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia: Results From a Randomised Clinical Trial
by Susan H. Hamilton & Dennis A. Revicki & Eric T. Edgell & Laura A. Genduso & Gary Tollefson - 481-493 Reconciling Decision Models With the Real World: An Application to Anaemia of Renal Failure
by Ya-Chen Tina Shih & Teresa L. Kauf - 495-505 Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy: Following Selective Serotonin Reuptake Inhibitor Therapy for Depression
by Robert I. Griffiths & Erin M. Sullivan & Richard G. Frank & Michael J. Strauss & Robert J. Herbert & Jon Clouse & Howard H. Goldman - 507-514 Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium
by Jean-Yves Reginster & Pierre Gillet & Wafa Ben Sedrine & Geoffrey Brands & Olivier Ethgen & Cecile defroidmont & Christiane Gosset
1999, Volume 15, Issue 4
- 317-337 The Clinical and Economic Potential of Cyclosporin Drug Interactions
by Jill E. Martin & A. Jamal Daoud & Timothy J. Schroeder & M. Royfirst - 339-355 Methodological Hurdles in Conducting Pharmacoeconomic Analyses
by J. Douglasrizzo & Neil R. Powe - 357-367 Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare: Matching the Art to the Science
by Emma McIntosh & Cam Donaldson & Mandy Ryan - 369-376 Utility Scores for Chronic Conditions in a Community-Dwelling Population
by Nicole Mittmann & Kostas Trakas & Nancy Risebrough & Barbara A. Liu - 377-384 Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care
by Gunnel Ragnarsont Tennvall & Nils Wilking - 385-393 Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making: A Hypothetical Model of Biotechnology Therapy in Gram-Negative Sepsis
by Edward C.Y. Wang & Thaddeus H. Grasela & Cynthia A. Walawander - 395-404 Cost Analysis of the Treatment of Severe Spinal Spasticity With a Continuous Intrathecal Baclofen Infusion System
by M. Postma & Dettie Oenema & Symon Terpstra & Jelte Bouma & Hannah Kuipersupmeijer & Michiel J. Staal & Berry J. Middel - 405-417 Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Pharmacoeconomic Review
by Allan J. Coukell & Stuart Noble & Diana Faulds
1999, Volume 15, Issue 3
- 209-216 Primary Care Purchasing: Are Integrated Primary Care Provider/Purchasers the Way Forward?
by Stephen Peckham - 217-228 Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens
by John Urquhart - 229-240 The Economics of Multiple Sclerosis: Distribution of Costs and Relationship to Disease Severity
by Amy Nicole Grudzinski & Zafar Hakim & Emily R. Cox & J. Lyle Bootman - 241-256 Patient Self-Reports in Pharmacoeconomic Studies: Their Use and Impact on Study Validity
by Christopher Evans & Bruce Crawford - 257-268 Under-Utilisation of beta-Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications
by W. David Bradford & Jersey Chen & Harlan M. Krumholz - 269-278 New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use
by Martin Edwards - 279-289 Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
by Karl J. Krobot & Klaus Wenke & Bruno Reichart - 291-303 Pharmaceutical Price Regulation: A Study on the Impact of the Rate-of-Return Regulation in the UK
by Joan-Ramon Borrell - 305-311 Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma
by Carin A. Uyl-de Groot & Gert J. Ossenkoppele & Ivanne Buijt & Peter C. Huijgens
1999, Volume 15, Issue 2
- 119-127 Valuing Health-Related Quality of Life: Issues and Controversies
by Paul Dolan - 129-140 The Effect of Managed Care on Prescription Drug Costs and Benefits
by Alan Lyles & Francis B. Palumbo - 141-155 Determining Clinically Important Differences in Health Status Measures: A General Approach with Illustration to the Health Utilities Index Mark II
by Greg Samsa & David Edelman & Margaret L. Rothman & G. Rhys Williams & Joseph Lipscomb & David Matchar - 157-165 Health-Related Quality-of-Life Measurement in Patients with Parkinson's Disease
by Crispin Jenkinson & Ray Fitzpatrick & Viv Peto - 167-178 Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia
by Viggo Jonsson & Mogen Mork Hansen & Per Ljungman & Stein Kaasa - 179-195 Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS
by Stacey J. Ackerman & Erin M. Sullivan & Kathleen M. Beusterien & Howard M. Natter & Deborah F. Gelinas & Donald L. Patrick - 197-204 Approaches to Missing Data Inference Results from CaPSURE: An Observational Study of Patients with Prostate Cancer
by Deborah P. Lubeck & David J. Pasta & Scott C. Flanders & James M. Henning
1999, Volume 15, Issue 1
- 1-8 The Use of Meta-Analysis in Cost-Effectiveness Analysis: Issues and Recommendations
by Sanjay Saint & David L. Veenstra & Sean D. Sullivan - 9-18 Willingness to Pay as a Measure of Health Benefits
by Mohan V. Bala & Josephine A. Mauskopf & Lisa L. Wood - 19-46 Evaluating Health-Related Quality-of-Life Outcomes in Patients with Congestive Heart Failure: A Review of Recent Randomised Controlled Trials
by Nancy K. Leidy & Anne M. Rentz & Teresa M. Zyczynski - 47-74 Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease
by Joel W. Hay & Winnie M. Yu & Talat Ashraf - 75-83 Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain
by F. Javier Jimenez & Pilar Guallar-Castillon & Carlos Rubio Terres & Eliseo Guallar - 85-95 Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia
by Giampaolo Bucaneve & Francesco Menichetti & Albano Del Favero - 97-113 Economic Evaluation of Antibacterials in the Treatment of Acute Sinusitis
by Claudine Laurier & Jean Lachaine & Murray Ducharme
1998, Volume 14, Issue 6
- 597-601 Are Mental Health Services Losing Out in the US Under Managed Care?
by Dale L. Johnson - 603-611 Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs
by Theodore H. Wein & Susan L. Hickenbottom & Andrei V. Alexandrov - 613-627 A Review of Quality of Life in Alzheimer's Disease: Part 2: Issues in Assessing Drug Effects
by Sam S. Salek & Melvyn D. Walker & Antony J. Bayer - 629-637 Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption: A Study of Managed-Care Organisation Enrollees
by Hind T. Hatoum & Sheldon X. Kong & Christopher M. Kania & Josephine M. Wong & Wallace B. Mendelson - 639-652 The Use and Cost of HIV Service Provision in England in 1996
by Eduard J. Beck & Keith Tolley & Amanda Power & Sundhiya Mandalia & Philippa Rutter & Junichi Izumi & Jeni Beecham & Alistair Gray & David Barlow & Philippa Easterbrook & Martin Fisher & John Innes & George Kinghorn & Bibhat Mandel & Anton Pozniak & Allan Tang & David Tomlinson & Ian Williams - 653-669 Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the Perspective of Statutory Health Insurance
by Peter K. Schadlich & Eduard Huppertz & Josef Georg Brecht - 671-684 Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
by Maureen P.M.H. Rutten-van Molken & Eddy K.A. van Doorslaer & M. Denise Till - 685-690 Fosphenytoin: Pharmacoeconomic Implications of Therapy
by Stephen M. Holliday & Paul Benfield & Greg L. Plosker - 691-708 Cyclosporin Microemulsion (Neoral(R)) Use of trade name is for product identification, and does not imply endorsement.: A Pharmacoeconomic Review of its Use Compared with Standard Cyclosporin in Renal and Hepatic Transplantation
by Allan J. Coukell & Greg L. Plosker - 709-714 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
by Linda D. MacKeigan - 709-714 Common Errors and Controversies in Pharmacoeconomic Analyses
by Stephen Palmer & Sarah Byford
1998, Volume 14, Issue 5
- 465-470 Willingness To Pay: What's in a Name?
by Amiram Gafni - 471-479 Pharmaceutical Reference Prices: How do They Work in Practice?
by Michael Dickson & Heinz Redwood - 481-498 A Review of the Economics of the Prevention and Control of Rabies: Part 2: Rabies in Dogs, Livestock and Wildlife
by Martin I. Meltzer & Charles E. Rupprecht - 499-530 A Review of Quality of Life in Alzheimer's Disease: Part 1: Issues in Assessing Disease Impact
by Melvyn D. Walker & Sam S. Salek & Antony J. Bayer - 531-539 Urge Incontinence: Quality of Life and Patients' Valuation of Symptom Reduction
by Richard M. O'Conor & Magnus Johannesson & Steven L. Hass & Gisela Kobelt-Nguyen - 541-557 Cost Effectiveness of Pramipexole in Parkinson's Disease in the US
by Thomas J. Hoerger & Mohan V. Bala & Clayton Rowland & Marianne Greer & Elizabeth A. Chrischilles & Robert G. Holloway - 559-573 Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis
by Andrew J. Rosner & Daniel T. Grima & George W. Torrance & Cathy Bradley & Jonathan D. Adachi & Rolf J. Sebaldt & Donald J. Willison - 575-588 Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in Greece
by Lycurgus Liaropoulos & Maria Spinthouri & Theodore Ignatiades & Georgia Ifandi & Fanis Katostaras & Emmanuel Diamantopoulos
1998, Volume 14, Issue 4
- 341-348 Does Managed Care Fuel Pharmaceutical Industry Growth?
by Michael D. Murray & Frank W. Deardorff - 349-355 Mega-Mergers in the Pharmaceutical Industry: In Whose Interests?
by Alain Li Wan Po - 357-363 The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis
by Douglas Coyle & Karen M. Lee - 365-383 A Review of the Economics of the Prevention and Control of Rabies: Part 1: Global Impact and Rabies in Humans
by Martin I. Meltzer & Charles E. Rupprecht - 385-394 Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring
by Richard L. Slaughter & Diane M. Cappelletty - 395-403 The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency
by Leona Hakkaart-van Roijen & Albert Beckers & Achille Stevenaert & Frans F.H. Rutten - 405-422 A Method to Select an Instrument for Measurement of HR-QOL for Cross-Cultural Adaptation Applied to Dermatology
by Adolfo Ga de Tiedra & Joan Mercadal & Xavier Badia & Jose Ma Mascaro & Rafael Lozano - 423-432 Threshold Analysis of Helicobacter pylori Therapy
by Amnon Sonnenberg - 433-445 Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France
by Mark Nuijten & Lionel Hadjadjeba & Christopher Evans & John van den Berg - 447-459 Docetaxel: A Pharmacoeconomic Review of its Use in the Treatment of Metastatic Breast Cancer
by Harriet M. Lamb & Lynda R. Wiseman
1998, Volume 14, Issue 3
- 241-250 The Need for Pharmacoeconomic Evaluations in the NHS
by John P. Griffin - 251-257 Methodological Quality of Economic Modelling Studies: A Case Study with Hepatitis B Vaccines
by Tom Jefferson & Vittorio Demicheli - 259-268 Reporting Format for Economic Evaluation: Part II: Focus on Modelling Studies
by C. Nuijten & Marja H. Pronk & Mark J. A. Brorens & Yechiel A. Hekster & Jacques H. M. Lockefeer & Peter A. G. M. de Smet & Gouke Bonsel & Ary van der Kuy - 269-283 Outcomes of Pharmacological and Surgical Treatment for Obesity
by Jennifer Cerulli & Margaret Malone - 285-297 Cost Analysis of Palliative Care for Terminally Ill Cancer Patients in the UK After Switching from Weak to Strong Opioids
by Julian F. Guest & Warren M. Hart & Ronald F. Cookson - 299-312 The Economic Impact of Parkinson`s Disease: An Estimation Based on a 3-Month Prospective Analysis
by Richard C. Dodel & Marikka Singer & Rudolf Kohne-Volland & Thomas Szucs & Bernard Rathay & Erich Scholz & Wolfgang H. Oertel - 313-322 Cost Effectiveness of Immunoprophylaxis in the Prevention of Recurrent Infectious Rhinitis in Adults
by Gilles Berdeaux & Antoine Lafuma & Anne-Marie Perruchet & Francis Fagnani - 323-333 Costs and Effects Associated with a Community Pharmacy-Based Smoking-Cessation Programme
by Grainne E. Crealey & James C. McElnay & Terry A. Maguire & Ciaran O'Neill - 335 Methodological Quality of Economic Modelling Studies: A Case Study with Hepatitis B Vaccines
by Michelle Wilde
1998, Volume 14, Issue 2
- 143-148 Cost-of-Illness Studies: Useful for Health Policy?
by Marc A. Koopmanschap - 149-150 Update on Clinical Research Summit in US
by Jay Moskowitz & James N. Thompson - 151-158 The Role of Clinical Pathways in Reducing the Economic Burden of Stroke
by Douglas J. Lanska - 159-163 Reporting Format for Economic Evaluation: Part I: Application to the Dutch Healthcare System
by Mark J.C. Nuijten & Mark J.A. Brorens & Yechiel A. Hekster & Ary van der Kuy & Jacques H. M. Lockefeer & Per A.G.M. de Smet & Gouke Bonsel & Marja H. Pronk - 165-174 Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS: An Overview and Methodological Discussion
by Kenneth A. Freedberg & A. David Paltiel - 175-189 A Review of the Pharmacoeconomics of Pharmaceutical Care
by Richard J. Plumridge & Richard E. Wojnar-Horton - 191-199 Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis: The Impact on Costs and Outcomes in the UK
by Chris J. McCabe & Ron L. Akehurst & Jeff Kirsch & Malcolm Whitfield & Martin Backhouse & Anthony D. Woolf & David L. Scott & Paul Emery & Ian Haslock - 201-207 Quality of Life Following a Change in Therapy for Diabetes Mellitus
by Mirjana Pibernik-Okanovic & Silvija Szabo & Zeljko Melko - 209-216 Cost Effectiveness of Screening for Subclinical Hypothyroidism in the Elderly: A Decision-Analytical Model
by Massimo Bona & Ferruccio Santini & Giovanni Rivolta & Enzo Grossi & Roberto Grilli - 217-236 Pravastatin: A Pharmacoeconomic Review of its use in Primary and Secondary Prevention of Coronary Heart Disease
by Allan J. Coukell & Michelle I. Wilde
1998, Volume 14, Issue 1
- 1-9 A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing?
by Michael F. Drummond - 11-17 The Role of Pharmacoeconomic Evaluations in Disease Management
by Kenneth Chang & David Nash - 19-25 The Impact of Managed Care on Clinical Research
by Martin McKee & Elias Mossialos - 27-48 Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
by Adalsteinn D. Brown & Alan M. Garber - 49-58 The Economics of TRACE: A Cost-Effectiveness Analysis of Trandolapril in Postinfarction Patients with Left Ventricular Dysfunction
by Claude LePen & Herve Lilliu & Thomas Keller & Sylvie Fiessinger - 59-70 The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients: A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin
by Michael J. Koren & Dean G. Smith & Donald B. Hunninghake & Michael H. Davidson & James M. McKenney & Stuart R. Weiss & Helmut G. Schrott & Robert W. Jr Henley & Perry Tresh & Richard W. McLain & Rebecca G. Bakker-Arkema & Donald M. Black - 71-77 A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information
by Robert S. Woodward & Leah Amir & Mark A. Schnitzler & Daniel C. Brennan - 79-95 The Use of Decision-Analytical Modelling in Economic Evaluation of Patch Testing in Allergic Contact Dermatitis
by Rukmini Rajagopalan & Roger T. Anderson & Syam Sarma & Carol Retchin & John Jones - 97-133 Risperidone: A Pharmacoeconomic Review of its Use in Schizophrenia
by Rachel H. Foster & Karen L. Goa - 135-137 `The Pros and Cons of a Single Euro-Price for Drugs' and `The Economics of Parallel Trade'
by Patricia Danzon & Adrian Towse - 135-137 `The Pros and Cons of a Single Euro-Price for Drugs' and `The Economics of Parallel Trade'
by Joan Rovira
1998, Volume 13, Issue 6
- 653-657 The Dilemma of New Drugs: Are Costs Rising Faster than Effectiveness?
by James Mason & Nick Freemantle - 659-666 Common Errors and Controversies in Pharmacoeconomic Analyses
by Sarah Byford & Stephen Palmer - 667-676 The Economic Burden of Migraine to Society
by Michel D. Ferrari - 677-686 Socioeconomics of a Global Leprosy Eradication Programme
by Sharad S. Naik & Ramaswamy Ganapati - 687-696 The Influence of Ill-Health Experience on the Valuation of Health
by Xavier Badia & Michael Herdman & Paul Kind - 697-705 Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy
by Aslam H. Anis & Robert S. Hogg & Xiao-hua Wang & Benita Yip & Anita Palepu & Julio S. G. Montaner & Michael V. O'Shaughnessy & Martin T. Schechter